Holen Sie sich die Stockscreener-App
151.56
1.41%
-2.17
Schlusskurs vom Vortag:
$153.73
Offen:
$154.42
24-Stunden-Volumen:
1.85M
Relative Volume:
0.65
Marktkapitalisierung:
$32.22B
Einnahmen:
$742.00K
Nettoeinkommen (Verlust:
$-1.37B
KGV:
-21.43
EPS:
-7.0731
Netto-Cashflow:
$-1.07B
1W Leistung:
+4.05%
1M Leistung:
+7.11%
6M Leistung:
+113.86%
1J Leistung:
+290.62%
1-Tages-Spanne:
$151.44
$156.25
1-Wochen-Bereich:
$141.00
$156.25
52-Wochen-Spanne:
$34.00
$156.25
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
650-481-6801
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-02-27 | Fortgesetzt | UBS | Buy |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Total equity of Revolution Medicines, Inc. – BMV:RVMD - TradingView
Price to earnings ratio of Revolution Medicines, Inc. – BMV:RVMD - TradingView
Revolution Medicines, Inc. Balance Sheet – BMV:RVMD - TradingView
Revolution Medicines stock hits all-time high at 155.72 USD By Investing.com - Investing.com Nigeria
RVMD Initiated Coverage by BernsteinPrice Target Announced at $151 - GuruFocus
Revolution Medicines stock hits all-time high at 155.72 USD - Investing.com
Bernstein Initiates Revolution Medicines at Market Perform - Moomoo
Revolution Medicines to host webcast on phase 3 trial results By Investing.com - Investing.com Australia
RVMD reports wider-than-expected loss in Q1, raises '26 expense view - MSN
Revolution Medicines to host webcast on phase 3 trial results - Investing.com UK
Bernstein initiates Revolution stock coverage at Market Perform on valuation - Investing.com UK
Revolution Medicines (RVMD) Coverage Initiated with Market Perfo - GuruFocus
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation - The Manila Times
Pancreatic cancer trial results prompt May 31 Revolution Medicines call - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Eagle Health Investments LP Makes New $9.23 Million Investment in Revolution Medicines, Inc. $RVMD - MarketBeat
Is Daraxonrasib’s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)? - Yahoo Finance
Revolution Medicines Recasts RAS Story With Phase 3 Win And New Firepower - simplywall.st
Profund Advisors LLC Has $2.15 Million Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Needham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider Loss - Insider Monkey
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Revolution Medicines, Inc.Common Stock (NQ: RVMD - FinancialContent
Truist assumes Revolution stock coverage with buy on cancer drug potential - Investing.com
Revolution Medicines, Inc. (RVMD) Stock Analysis: Biotech Heavyweight with 24% Potential Upside - DirectorsTalk Interviews
JP Morgan Maintains Revolution Medicines (RVMD) Overweight Recommendation - MSN
Assessing Revolution Medicines (RVMD) Valuation After A Powerful Multi Year Shareholder Return Run - Yahoo Finance
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report - Sahm
Janus Henderson Group reports stake in Revolution Medicines (RVMD) — 9.77M shares - Stock Titan
Why (RVMD) Price Action Is Critical for Tactical Trading - Stock Traders Daily
AIHC Capital Management Ltd Acquires New Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters
Revolution Medicines (RVMD) down 8.8% since last earnings report: Can it rebound? - MSN
Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside Potential - TipRanks
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry - TipRanks
How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough - The New York Times
Revolution Medicines outlines $1.7B-$1.8B in 2026 GAAP operating expenses while expanding RASolve 301 to 590 patients - MSN
Q2 EPS Forecast for Revolution Medicines Lowered by Analyst - MarketBeat
Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib - Insider Monkey
Is It Too Late To Consider Revolution Medicines (RVMD) After A 240% One Year Surge? - Yahoo Finance
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $263 - Moomoo
Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent Surge In Price? - simplywall.st
Should RVMD’s Wider Losses and Daraxonrasib Progress Require Action From Revolution Medicines (RVMD) Investors? - simplywall.st
10 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know - Pancreatic Cancer Action Network
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.20%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):